Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60,000
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.
详细描述
Lung cancer is the leading cause of cancer-related deaths in China. The recent decade witnessed rapid evolving of demographics, pathological features and prognoses of patients with surgically resected lung cancers. The introduction of minimally invasive surgery (MIS) concept and techniques, targeted therapy and immunotherapy changed treatment landscape for patients with surgically resected lung cancers. With more early-stage lung cancers discovered due to the application of CT screening, questions focusing on extent of lung resection, lymph node dissection, application of targeted or immune-therapy to early-stage lung cancers are emerging. This study aims to create a cohort of patients with surgically resected lung cancers and an analytic framework to address the aforementioned clinical questions.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age above
- •Have received surgical resection for lung malignancies.
排除标准
- •Participants whose data are of low quality, poor completeness or poor internal linkage.
结局指标
主要结局
Overall survival
时间窗: January 2014 to December 2031
Time from surgery to death from any cause.
次要结局
- Pathological characteristics of included participants(January 2014 to December 2028)
- Features associated with overall survival(First analysis is anticipated to be performed from April to August 2024; the final analysis is anticipated in 2032.)
- Treatment patterns of included participants(January 2014 to December 2028)
- Baseline characteristics of included participants(January 2014 to December 2028)
